"10.1371_journal.pone.0066125","plos one","2013-06-20T00:00:00Z","Giedre Gefenaite; Margot Tacken; Jens Bos; Irina Stirbu-Wagner; Joke C Korevaar; Ronald P Stolk; Bert Wolters; Marc Bijl; Maarten J Postma; Jan Wilschut; Kristin L Nichol; Eelko Hak","Department of Pharmacy, Unit of PharmacoEpidemiology & PharmacoEconomics (PE2), University of Groningen, Groningen, The Netherlands; Department of Epidemiology, University Medical Centre Groningen, University of Groningen, The Netherlands; Scientific Institute for Quality of Healthcare (IQ healthcare), Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; NIVEL, Netherlands Institute for Health Services Research, Utrecht, The Netherlands; Community Health Services, Groningen, The Netherlands; Department of Internal Medicine and Rheumatology, Martini Hospital, Groningen, The Netherlands; Department of Medical Microbiology, Molecular Virology Section, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands; Research Service, Veterans Affairs Medical Centre, Minneapolis, Minnesota, United States of America; Department of Medicine, University of Minnesota, Minneapolis, Minnesota, United States of America","Analyzed the data: GG EH RPS. Contributed reagents/materials/analysis tools: GG EH RPS BW MB MJP JW MT JB ISW JCK KLN. Wrote the paper: GG. Study concept and design: GG EH RPS BW MB MJP JW MT JB ISW JK KLN. Critical revision of the manuscript for important intellectual content: MT JB ISW JCK RPS BW MB MJP JW KLN EH.","Kristin Nichol has served as a consultant to or on medical advisory boards for vaccine manufacturers in the past (or may in the future). Marc Bijl received research grants from Novartis and Sanofi, inclusive those interested in the subject of the manuscript; however, no financial support for contribution to this study was received. Joke Korevaar received a research grant from AstraZeneca, which was not related to the subject of this manuscript. Maarten J. Postma received research grants, honoraria and travel stipends from GSK Zeist NL, Amgen, GSK Bio Brussels, Shire, Pfizer, SPMSD NL, SPMSD Brussels, MSD, Sanofi, Novartis, Novo Nordisk, Jansen, Roche, Preglem, Boehringer Ingelheim, Viiv, Astra Zeneca, inclusive those interested in the subject of the manuscript; however, no financial support for the contribution to this study was received. Jan Wilschut received research grants, honoraria and travel stipends from GlaxoSmithKline (Zeist, Netherlands), SPMSD (Lyon, France), Crucell (Leiden, Netherlands), Solvay Biologicals (Weesp, Netherlands), Roche (Woerden, Netherlands), Mymetics (Leiden, Netherlands), Mucosis (Groningen, Netherlands), GlaxoSmithKline (Rixensart, Belgium), inclusive those interested in the subject of the manuscript; however, no financial support for contribution to this study was received. This does not alter the authorsâ€™ adherence to all the PLOS ONE policies on sharing data and materials. Other authors have declared that no competing interests exist.","2013","06","Giedre Gefenaite","GG",12,FALSE,NA,NA,3,1,TRUE,TRUE,FALSE,0,NA,FALSE
